Form 8-K - Current report:
SEC Accession No. 0001493152-25-003977
Filing Date
2025-01-28
Accepted
2025-01-28 16:00:24
Documents
16
Period of Report
2025-01-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 41963
2 ex99-1.htm EX-99.1 14854
3 ex99-1_001.jpg GRAPHIC 15877
  Complete submission text file 0001493152-25-003977.txt   305876

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE bctx-20250124.xsd EX-101.SCH 3750
5 XBRL DEFINITION FILE bctx-20250124_def.xml EX-101.DEF 29998
6 XBRL LABEL FILE bctx-20250124_lab.xml EX-101.LAB 36631
7 XBRL PRESENTATION FILE bctx-20250124_pre.xml EX-101.PRE 27021
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5667
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 25564043
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)